Arrowhead Research | ARWR - Cash And Equivalent


Arrowhead Research reported $147.53M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Agios Pharmaceuticals USD 99.65M 13.95M Jun/2026
Alnylam Pharmaceuticals USD 1.71B 2.46M Jun/2026
Anika Therapeutics USD 38.41M 2.61M Jun/2026
Arrowhead Research USD 147.53M 54.11M Mar/2026
Heron Therapeutics USD 26.12M 2.53M Mar/2026
Incyte USD 3.98B 33.45M Jun/2026
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
Ligand Pharmaceuticals USD 115.08M 59.85M Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Moderna USD 1.72B 185M Jun/2026
Nektar Therapeutics USD 149.58M 134.46M Mar/2026
Novartis USD 7.62B 739M Jun/2026
Sarepta Therapeutics USD 571.15M 106.7M Jun/2026
TG Therapeutics USD 612.25M 170.04M Jun/2026
Ultragenyx Pharmaceutical USD 125M 50M Jun/2026
Vertex Pharmaceuticals USD 7.85B 605.7M Jun/2026
Xencor USD 44.66M 30.49M Jun/2026